Elizabeth Macintyre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11584951/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet, The, 2000, 356, 203-208.	13.7	698
2	Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia. Cancer Cell, 2011, 19, 138-152.	16.8	545
3	Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study. Journal of Clinical Oncology, 2009, 27, 911-918.	1.6	506
4	Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaresults of the prospective multicenter LALA-94 trial. Blood, 2002, 100, 2357-2366.	1.4	344
5	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, The, 2016. 388. 565-575.	13.7	328
6	BLUEPRINT to decode the epigenetic signature written in blood. Nature Biotechnology, 2012, 30, 224-226.	17.5	323
7	Presentation and Long-Term Follow-up of Refractory Celiac Disease: Comparison of Type I With Type II. Gastroenterology, 2009, 136, 81-90.	1.3	319
8	Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 2007, 109, 1408-1413.	1.4	300
9	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood, 2014, 123, 3739-3749.	1.4	281
10	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood, 2010, 115, 3215-3223.	1.4	243
11	High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 2000, 96, 2862-2869.	1.4	241
12	NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood, 2009, 113, 3918-3924.	1.4	207
13	Toward a <i>NOTCH1/FBXW7/RAS/PTEN</i> –Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. Journal of Clinical Oncology, 2013, 31, 4333-4342.	1.6	202
14	Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. Journal of Clinical Oncology, 2015, 33, 2963-2974.	1.6	202
15	Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. Journal of Clinical Investigation, 2003, 111, 381-387.	8.2	186
16	Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. Journal of Experimental Medicine, 2010, 207, 731-750.	8.5	169
17	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. British Journal of Haematology, 2009, 145, 624-636.	2.5	163
18	Analysis of TCR, pTα, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood, 2003, 101, 2693-2703.	1.4	152

#	Article	IF	CITATIONS
19	CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRÂÂ lineage. Blood, 2003, 102, 1000-1006.	1.4	148
20	Early Response–Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. Journal of Clinical Oncology, 2017, 35, 2683-2691.	1.6	134
21	Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity, 2016, 45, 610-625.	14.3	131
22	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood, 2015, 126, 604-611.	1.4	130
23	Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell, 2006, 10, 363-374.	16.8	119
24	Molecular detection of t(8;21)/AML1â€ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. British Journal of Haematology, 1996, 92, 855-865.	2.5	118
25	Enteropathy associated T cell lymphoma in celiac disease: A large retrospective study. Digestive and Liver Disease, 2013, 45, 377-384.	0.9	118
26	Clinical Impact of <i>NOTCH1</i> and/or <i>FBXW7</i> Mutations, <i>FLASH</i> Deletion, and <i>TCR</i> Status in Pediatric T-Cell Lymphoblastic Lymphoma. Journal of Clinical Oncology, 2012, 30, 1966-1973.	1.6	111
27	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. Journal of Clinical Oncology, 2018, 36, 2514-2523.	1.6	99
28	Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica, 2010, 95, 324-328.	3.5	98
29	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood, 2018, 131, 289-300.	1.4	97
30	Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood, 2012, 119, 4476-4479.	1.4	96
31	Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood, 2004, 104, 4173-4180.	1.4	94
32	FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood, 2003, 102, 2198-2204.	1.4	90
33	Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology, 2003, 125, 40-46.	1.3	89
34	PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood, 2011, 117, 7090-7098.	1.4	76
35	Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. Journal of Clinical Oncology, 2016, 34, 572-580.	1.6	76
36	Diagnostic Yield of Capsule Endoscopy in Refractory Celiac Disease. American Journal of Gastroenterology, 2012, 107, 1546-1553.	0.4	74

#	Article	IF	CITATIONS
37	M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood, 2003, 101, 1277-1283.	1.4	72
38	Characteristic Pattern of Chromosomal Imbalances in Posttransplantation Lymphoproliferative Disorders: Correlation with Histopathological Subcategories and EBV Status. Transplantation, 2005, 80, 176-184.	1.0	65
39	Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nature Communications, 2016, 7, 10087.	12.8	65
40	The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. Blood, 2000, 96, 2254-2261.	1.4	63
41	Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood, 2005, 105, 3072-3078.	1.4	63
42	Small Intestinal CD4+ T-Cell Lymphoma Is a Heterogenous Entity With Common Pathology Features. Clinical Gastroenterology and Hepatology, 2014, 12, 599-608.e1.	4.4	61
43	Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy. PLoS ONE, 2015, 10, e0125024.	2.5	60
44	Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood, 2016, 127, 3040-3053.	1.4	60
45	An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica, 2016, 101, 732-740.	3.5	53
46	Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. The Lancet Gastroenterology and Hepatology, 2019, 4, 960-970.	8.1	52
47	Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood, 2011, 118, 5099-5107.	1.4	50
48	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica, 2016, 101, 336-345.	3.5	50
49	Oncogenetic landscape of lymphomagenesis in coeliac disease. Gut, 2022, 71, 497-508.	12.1	48
50	<i>JAK1</i> mutations are not frequent events in adult Tâ€ALL: a GRAALL study. British Journal of Haematology, 2010, 148, 178-179.	2.5	47
51	NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. Gut, 2019, 68, 1396-1405.	12.1	47
52	Hematopoietic stem cell quiescence and function are controlled by the CYLD–TRAF2–p38MAPK pathway. Journal of Experimental Medicine, 2015, 212, 525-538.	8.5	46
53	T Cell Receptor Genotyping and <i>HOXA/TLX1</i> Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome. Clinical Cancer Research, 2008, 14, 692-700.	7.0	43
54	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica, 2013, 98, 1711-1717.	3.5	41

ELIZABETH MACINTYRE

#	Article	IF	CITATIONS
55	SET-NUP214 is a recurrent $\hat{I}^{\hat{J}\hat{I}}$ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. Blood, 2014, 123, 1860-1863.	1.4	40
56	<i>DNMT3A</i> mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, 1617-1625.	3.5	40
57	Droplet Digital PCR Quantification of Mantle Cell Lymphoma Followâ€up Samples From Four Prospective Trials of the European MCL Network. HemaSphere, 2020, 4, e347.	2.7	36
58	Fluorescence In Situ Hybridization Analysis of Masked (8;21)(q22;q22) Translocations. Cancer Genetics and Cytogenetics, 1999, 112, 15-20.	1.0	35
59	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551.	5.2	35
60	Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of highâ€risk patients. British Journal of Haematology, 2014, 166, 50-59.	2.5	33
61	Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. Cancer Discovery, 2016, 6, 972-985.	9.4	33
62	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. Cell Reports, 2020, 30, 739-754.e4.	6.4	32
63	Extensive molecular mapping of TCRα/δ- and TCRβ-involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL. Blood, 2012, 120, 3298-3309.	1.4	31
64	Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators. Experimental Hematology, 2017, 51, 7-16.	0.4	29
65	Enteropathy-Associated T-Cell Lymphoma Complicating an Autoimmune Enteropathy. Gastroenterology, 2012, 142, 726-729.e3.	1.3	28
66	Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation. Gastroenterology, 2019, 156, 1206-1210.e1.	1.3	28
67	CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia, 2020, 34, 3228-3241.	7.2	27
68	Epigenetic Silencing Affects <scp> </scp> -Asparaginase Sensitivity and Predicts Outcome in T-ALL. Clinical Cancer Research, 2019, 25, 2483-2493.	7.0	25
69	Large Granular Lymphocytic Leukemia: A Treatable Form of Refractory Celiac Disease. Gastroenterology, 2012, 143, 1470-1472.e2.	1.3	23
70	Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. Blood, 2014, 124, 3023-3025.	1.4	21
71	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia, 2020, 34, 1730-1740.	7.2	21
72	Genetic polymorphisms in <i><scp>ARID</scp>58</i> , <i><scp>CEBPE</scp></i> , <i><scp>KZF</scp>1</i> and <i><scp>CDKN</scp>2A</i> in relation with risk of acute lymphoblastic leukaemia in adults: a <scp>G</scp> roup for <scp>R</scp> esearch on <scp>A</scp> dult <scp>A</scp> cute <scp>L</scp> ymphoblastic <scp>L</scp> eukaemia (GRAALL) study. British Journal of Haematology, 2012, 159, 599-613.	2.5	18

#	Article	IF	CITATIONS
73	Feline low-grade intestinal T cell lymphoma: a unique natural model of human indolent T cell lymphoproliferative disorder of the gastrointestinal tract. Laboratory Investigation, 2021, 101, 794-804.	3.7	16
74	Targeting IRAK1 in T-Cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 18956-18965.	1.8	16
75	Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation. Journal of Experimental Medicine, 2020, 217, .	8.5	15
76	Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Science Translational Medicine, 2021, 13, .	12.4	13
77	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1981-1988.	5.2	12
78	A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2019, 21, 111-122.	2.8	12
79	Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematology,the, 2020, 7, e798-e807.	4.6	12
80	Acquired TET 2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of preâ€leukaemic clone resulting in T2―ALL and AML â€MO. Journal of Cellular and Molecular Medicine, 2017, 21, 1237-1242.	3.6	10
81	Array GH predicts prognosis in plasma cell postâ€ŧransplantation lymphoproliferative disorders. Genes Chromosomes and Cancer, 2017, 56, 221-230.	2.8	10
82	Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. Haematologica, 2020, 105, 1575-1581.	3.5	10
83	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. Journal of Hematology and Oncology, 2021, 14, 74.	17.0	10
84	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. Blood Cancer Journal, 2022, 12, 14.	6.2	10
85	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. Leukemia, 2018, 32, 1878-1882.	7.2	8
86	<i>IKZF1</i> alterations predict poor prognosis in adult and pediatric T-ALL. Blood, 2021, 137, 1690-1694.	1.4	8
87	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. Leukemia, 2021, 35, 724-736.	7.2	8
88	Adenylate kinase 2 expression and addiction in T-ALL. Blood Advances, 2021, 5, 700-710.	5.2	7
89	C/EBPA methylation is common in T-ALL but not in MO AML. Blood, 2009, 113, 1864-1866.	1.4	6
90	Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study Blood, 2004, 104, 2741-2741.	1.4	6

ELIZABETH MACINTYRE

#	Article	IF	CITATIONS
91	<i><scp>NAP</scp>1L1â€<scp>MLLT</scp>10</i> is a rare recurrent translocation that is associated with <i><scp>HOXA</scp></i> activation and poor treatment response in Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 174, 470-473.	2.5	5
92	Toward Pediatric T Lymphoblastic Lymphoma Stratification Based on Minimal Disseminated Disease and NOTCH1/FBXW7 Status. HemaSphere, 2021, 5, e641.	2.7	5
93	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. Modern Pathology, 2022, 35, 1227-1235.	5.5	5
94	Acute monocytic leukemia with coexpression of minorBCR–ABL1 andPICALM–MLLT10 fusion genes along with overexpression ofHOXA9. Genes Chromosomes and Cancer, 2006, 45, 575-582.	2.8	4
95	RÃ1e du pathologiste dans le diagnostic de la maladie cÅ"liaque et de ses complications. Revue Francophone Des Laboratoires, 2018, 2018, 30-38.	0.0	3
96	Early thymic precursorâ€like lymphomatous presentation of the <i><scp>ETV</scp>6</i> â€ <i><scp>NCOA</scp>2</i> translocation. British Journal of Haematology, 2018, 181, 392-394.	2.5	2
97	Immature acute leukaemias: lessons from the haematopoietic roadmap. FEBS Journal, 2022, 289, 4355-4370.	4.7	2
98	Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. Leukemia, 2021, , .	7.2	2
99	Hematopoietic stem cell quiescence and function are controlled by the CYLD–TRAF2–p38MAPK pathway. Journal of Cell Biology, 2015, 209, 2091OIA63.	5.2	1